Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Oxford Drug Design, a UK-based bacterial infection medicine developer spun out of University of Oxford, obtained £2.2m ($2.8m) on Tuesday including equity from Angel CoFund, O2H Ventures and undisclosed new investors, as well as grant money from a UK government competition intended to foster UK-China research collaborations. The spinout will deploy the capital for its research and discovery efforts, aimed at combatting anti-microbial resistance in humans and animals by treating infections with new small molecule drugs and traditional Chinese medicines.…
